# How a change near one end can affect peptide breakdown

- Article ID: research-064
- Product: CJC-1295 No DAC (cjc-1295-no-dac-623, cjc-1295-no-dac-520, cjc-1295-no-dac-609)
- Canonical page: https://heritagebiolabs.com/research-library/articles/064-how-a-change-near-one-end-can-affect-peptide-breakdown
- Product collection: https://heritagebiolabs.com/research-library/products/cjc-1295-no-dac
- Product page: https://heritagebiolabs.com/product/cjc-1295-no-dac-623
- Product page: https://heritagebiolabs.com/product/cjc-1295-no-dac-520
- Product page: https://heritagebiolabs.com/product/cjc-1295-no-dac-609
- Reading focus: Mechanisms & biology (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 1989, 2024

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

A peptide is a short chain of amino acids connected by peptide bonds. Those bonds let the chain carry a signal, and specialized enzymes can cut them to end that signal. CJC-1295 No DAC generally denotes Mod GRF (1–29), a growth hormone–releasing hormone (GHRH) fragment with four substitutions and no albumin-binding attachment. One of those substitutions helps frame a question about how researchers study peptide stability. [1]

An older study from 1989 exposed natural GHRH and several shortened relatives to plasma under laboratory conditions. The investigators found that the enzyme dipeptidyl peptidase IV, also called DPP-4, could cut away the first two amino acids. Putting a mirror-image D-amino acid at position one or two prevented that particular cut in the molecules studied. The investigators also identified cuts elsewhere in the chain that involved other enzymes. [2]

That distinction matters because stability has several meanings. Blocking one cleavage route can preserve a particular bond while leaving other routes open. An experiment following the intact peptide in a tube answers a narrower question than a human study measuring how long the active compound remains in circulation. Both questions differ from how long a change in downstream hormones lasts. [2]

The FDA described the second residue of the no-DAC form as D-alanine. No recent primary human study was identified here that measured how long this exact compound remains intact in circulation. The 1989 work gives the biochemical rationale for testing such a substitution, but its findings belong to the sequences and experimental conditions the authors examined. A duration estimate for Mod GRF (1–29) would require direct measurements of that molecule and, ideally, separate measurements of any remaining hormone response. [1, 2]

## Sources

1. U.S. Food and Drug Administration. December 4, 2024 Pharmacy Compounding Advisory Committee (PCAC) Meeting. FDA briefing document on CJC-1295-related bulk drug substances (publication 2024-12-04). <https://www.fda.gov/media/183819/download>
2. Frohman LA et al. Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. Journal of Clinical Investigation (publication 1989-05). <https://pubmed.ncbi.nlm.nih.gov/2565342/>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 013 - Cagrilintide and CJC-1295 No DAC.docx; article 64; content SHA-256 fb8bc9c4c71964866a502bc158962622ef113deb38ffb2198f9c4f57604ec0ae.
